Chain Drug Review - FDA grants approval to Eli Lilly’s Strattera
Monday, January 5th, 2009INDIANAPOLIS — Eli Lilly and Co. has received Food and Drug Administration clearance for Strattera (atomoxetine HCl) for maintenance treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Strattera, a selective nor…
